MV-NIS

P1, N=9, Completed, Mayo Clinic | Recruiting --> Completed | N=30 --> 9 | Trial completion date: Sep 2024 --> Apr 2024 | Trial primary completion date: Sep 2024 --> Apr 2024

Considering the heterogeneity of PDAC and the complexity of biological therapies such as OVs, no single biomarker can explain the spectrum of response patterns. For selection of a particular OV, PDAC molecular subtype, ISG expression as well as activation of distinct signaling and metabolic pathways should be considered. Combination therapies can overcome resistance in specific constellations. Overall, oncolytic virotherapy is a viable treatment option for PDAC, which warrants further development. This study highlights the need for personalised treatment in OVT. By providing all primary data, this study provides a rich source and guidance for ongoing developments.

P1/2, N=34, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=57 --> 34

P1/2, N=57, Recruiting, Mayo Clinic | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024

We reviewed seven virus types that have been investigated in past or ongoing pediatric tumor clinical trials: adenovirus (AdV-tk, Celyvir, DNX-2401, VCN-01, Ad-TD-nsIL-12), herpes simplex virus (G207, HSV-1716), vaccinia (JX-594), reovirus (pelareorep), poliovirus (PVSRIPO), measles virus (MV-NIS), and Senecavirus A (SVV-001). However, the antitumor effects of OVT remain variable depending on tumor type and viral agent used. Although the widespread adoption of OVT faces many challenges, we are optimistic that OVT will play an important role alongside standard chemotherapy and radiotherapy for the treatment of malignant pediatric solid tumors in the future.

P1/2, N=57, Recruiting, Mayo Clinic | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024

P1, N=8, Completed, Vyriad, Inc. | Active, not recruiting --> Completed

P1, N=34, Completed, Sabine Mueller, MD, PhD | Recruiting --> Completed | Trial completion date: May 2024 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023

P1, N=8, Active, not recruiting, Vyriad, Inc. | Recruiting --> Active, not recruiting | N=16 --> 8 | Trial completion date: Dec 2022 --> May 2023 | Trial primary completion date: Apr 2022 --> May 2023

P1, N=12, Completed, Mayo Clinic | Active, not recruiting --> Completed

P1, N=46, Recruiting, Sabine Mueller, MD, PhD | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Dec 2022 --> Dec 2023

P1, N=46, Recruiting, Sabine Mueller, MD, PhD | Trial completion date: Nov 2022 --> May 2023 | Trial primary completion date: Jun 2022 --> Dec 2022

P1/2, N=57, Recruiting, Mayo Clinic | Trial completion date: Mar 2022 --> Dec 2023 | Trial primary completion date: Mar 2022 --> Dec 2023

P1, N=12, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2021 --> Dec 2022

Current anti-myeloma therapies (conventional chemotherapies, immunomodulatory drugs i.e., thalidomide and its' analogues, proteasome inhibitors, monoclonal antibodies, and radiotherapy) initially substantially debulk tumour burden, but after a period of remission 'plateau phase' disease invariably relapses due to tumour recrudescence from foci of minimal residual disease (MRD) and accumulating drug resistance...This review will discuss the potential use of oncolytic virus (OV) therapies in the treatment of myeloma. Specifically, it will focus on preclinical studies using DNA viruses (adenovirus (Ad), vaccinia virus (VV), myxoma virus (MYXV), and herpes simplex virus (HSV)), RNA viruses (reovirus (reo), coxsackie virus, measles virus (MV) and bovine viral diarrhoea virus (BVDV), and vesicular stomatitis virus (VSV)), and on four types of viruses (VV, reo, MV-NIS and VSV-IFNβ-NIS) that have been assessed clinically in a small number of myeloma patients.

P1, N=46, Recruiting, Sabine Mueller, MD, PhD | Trial primary completion date: Nov 2021 --> Jun 2022

P1/2, N=57, Recruiting, Mayo Clinic | Trial completion date: Jun 2021 --> Mar 2022 | Trial primary completion date: Jun 2021 --> Mar 2022

P1, N=12, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2020 --> Dec 2021

We conducted first in human trials of intraperitoneal (IP) administration of the MV-CEA (expressing the human carcinoembryonic antigen) and MV-NIS strains and we demonstrated excellent safety and evidence of biologic activity as indicated by decreases in tumor marker CA125, and promising median overall survival of 26.6 mo (vs expected survival of only 6-12 mos) in a heavily pretreated patient population (Galanis et al, Cancer Res)... Adipose tissue derived MSC can safely deliver MV strains without dose limiting toxicity being encountered. This form of cell based delivery resulted in cell dose dependent improvement in clinical outcome and development of antitumor cellular and humoral immune responses. A phase II trial of this approach is ongoing with 9 pts having enrolled todate; updated data will be presented at the meeting.

P1, N=12, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2019 --> Dec 2020